NDAORALCAPSULE
Approved
Nov 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CENTRAX (prazepam) is an oral benzodiazepine capsule approved in 1979 by Pfizer for anxiety disorders. The drug works as a central nervous system depressant, enhancing GABA receptor activity to reduce neuronal excitability. Prazepam is a long-acting benzodiazepine indicated for generalized anxiety and related conditions.
LOE Approaching
With LOE approaching and 30% competitive pressure, the CENTRAX team is likely consolidating resources and shifting focus to defensive positioning or transition planning in a mature, competitive benzodiazepine market.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CENTRAX offers limited career expansion opportunity given its LOE-approaching status and zero linked job postings. Roles on this product typically focus on defending market share, managing generic competition, and optimizing operational efficiency rather than innovation or team growth.
Brand ManagerField Sales Representative
Worked on CENTRAX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.